Håvard Andreassen Sæverud
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Håvard Andreassen Sæverud has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Adam Dowrick
Respinor, Gaustadalleen 21, 0349, Oslo, Norway
1 shared publicationDag Jacobsen
Department of Acute Medicine, Oslo University Hospital, Oslo, Norway
1 shared publication- Ellen Johanne Annexstad
Department of Neurology, Unit for Congenital and Inherited Neuromuscular Disorders, Oslo University Hospital, Oslo, Norway
1 shared publication Espen Molden
Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway
1 shared publication- F. Borchsenius
Dept. of Pulmonary Medicine, Oslo University Hospital, Ullevål, Kirkeveien 166, 0407 Oslo, Norway
1 shared publication - H. Mellem
Dept. of Pulmonary Medicine, Oslo University Hospital, Ullevål, Kirkeveien 166, 0407 Oslo, Norway
1 shared publication
Latest Publications
- 24 January 2020
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 127 (1) , 47-51
Fatal liver failure after therapeutic doses of paracetamol in a patient with Duchenne muscular dystrophy and atypical pharmacogenetic profile of drug‐metabolizing enzymes
Paracetamol has a good safety profile, but pharmacogenetic differences in drug‐metabolizing enzymes may have an impact on its risk of hepatotoxicity. We present a case of fatal acute liver failure (ALF) after therapeutic doses of paracetamol in a patient with Duchenne muscular dystrophy, where pharmacogenetic screening was conducted. This 30‐year‐old man was electively admitted for a tracheostomy. A total of 14.5 g paracetamol was given over four days. He developed a severe ALF and died 11 days after admission. Pharmacogenetic screening showed absent CYP2D6 metabolism and increased CYP1A2 activity, which may have increased the formation of toxic intermediate metabolite, N‐acetyl‐p‐benzo‐quinone imine (NAPQI). He also had decreased function of UGT2B15, which increases the amount of paracetamol available for metabolism to NAPQI. Having a reduced muscle mass and thus a reduced glutathione levels to detoxify produced NAPQI may add to the risk of toxicity. This case may indicate that pharmacogenetic variability is of potential relevance for the risk of paracetamol‐induced hepatotoxicity in patients with neuromuscular diseases. Further studies should investigate if pharmacogenetic screening could be a tool to detect potentially increased risk of hepatotoxicity in these patients at therapeutic doses of paracetamol and hence provide information for selection of analgesic treatment.
- 24 January 2020
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 127 (1) , 47-51
Fatal liver failure after therapeutic doses of paracetamol in a patient with Duchenne muscular dystrophy and atypical pharmacogenetic profile of drug‐metabolizing enzymes
Paracetamol has a good safety profile, but pharmacogenetic differences in drug‐metabolizing enzymes may have an impact on its risk of hepatotoxicity. We present a case of fatal acute liver failure (ALF) after therapeutic doses of paracetamol in a patient with Duchenne muscular dystrophy, where pharmacogenetic screening was conducted. This 30‐year‐old man was electively admitted for a tracheostomy. A total of 14.5 g paracetamol was given over four days. He developed a severe ALF and died 11 days after admission. Pharmacogenetic screening showed absent CYP2D6 metabolism and increased CYP1A2 activity, which may have increased the formation of toxic intermediate metabolite, N‐acetyl‐p‐benzo‐quinone imine (NAPQI). He also had decreased function of UGT2B15, which increases the amount of paracetamol available for metabolism to NAPQI. Having a reduced muscle mass and thus a reduced glutathione levels to detoxify produced NAPQI may add to the risk of toxicity. This case may indicate that pharmacogenetic variability is of potential relevance for the risk of paracetamol‐induced hepatotoxicity in patients with neuromuscular diseases. Further studies should investigate if pharmacogenetic screening could be a tool to detect potentially increased risk of hepatotoxicity in these patients at therapeutic doses of paracetamol and hence provide information for selection of analgesic treatment.
- 6 November 2019
- Published by Springer Nature in Journal of Ultrasound
- Vol. 24 (1) , 15-22
Measuring diaphragm movement and respiratory frequency using a novel ultrasound device in healthy volunteers
To evaluate the ability of a novel ultrasound (US) device, DiaMon, to monitor diaphragm movement via its proxy liver movement, and compare it with the respired flow measured with a flowmeter, in awake and healthy volunteers. We wanted to (1) establish the optimal anatomical position for attaching the DiaMon device to the abdominal wall, and (2) evaluate the accuracy of continuous monitoring of respiratory frequency.
- 6 November 2019
- Published by Springer Nature in Journal of Ultrasound
- Vol. 24 (1) , 15-22
Measuring diaphragm movement and respiratory frequency using a novel ultrasound device in healthy volunteers
To evaluate the ability of a novel ultrasound (US) device, DiaMon, to monitor diaphragm movement via its proxy liver movement, and compare it with the respired flow measured with a flowmeter, in awake and healthy volunteers. We wanted to (1) establish the optimal anatomical position for attaching the DiaMon device to the abdominal wall, and (2) evaluate the accuracy of continuous monitoring of respiratory frequency.
- Open Access
- 8 July 2013
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 10, 4-6
The obstructive siblings: Relapsing polychondritis without chondritis?
- 8 July 2013
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 10, 4-6
Open AccessThe obstructive siblings: Relapsing polychondritis without chondritis?